Gene-silencing therapies may finally be able to reach hard-to-target organs like the brain and kidney by hitching a ride on the body’s own delivery vesicles, which naturally home to specific cell types and can deliver RNA drugs at far lower, safer doses.
ACCESS Health International
The promise of turning off the genetic drivers of devastating diseases is becoming an attainable reality, assuming these therapies can effectively reach the targeted cells. In controlled lab settings, delivering gene-silencing drugs into cells is relatively straightforward. Inside the human body is another story.
The drugs must travel through the bloodstream, evade immune defenses and enter only the intended cell types while bypassing all others. Most do not; instead, they accumulate in the liver, leaving patients whose diseases originate in other organs without effective options. A new method offers a compelling way forward: harnessing the body’s own delivery system.
Gene-silencing therapies use short strands of RNA to intercept and destroy the molecular instructions that produce harmful proteins. Regulatory agencies have already approved several such drugs, but nearly all succeed only in the liver. This occurs because the liver is easily accessible. It readily absorbs particles from the bloodstream, making it the default destination for most injected therapies.
Reaching other organs proves far more difficult. Often higher doses are needed. These increase the risk of toxicity and immune reactions. The brain poses an even greater challenge because a tightly regulated barrier prevents most circulating molecules from entering. Therefore, a gap persists between what works in vitro and what works in vivo, a defining obstacle in modern genetic medicine.
The body, however, already solves a version of this problem. Cells continuously release tiny membrane-bound bubbles known as extracellular vesicles, or exosomes. These structures carry proteins and RNA between cells and act as a natural communication network.
MORE FOR YOU
Think of most conventional drugs as bulk shipping. They circulate widely, and much of the “cargo” ends up in central hubs like the liver rather than at the intended destination. Exosomes, by contrast, function more like the body’s own courier service or Amazon Prime. They carry built-in address labels that guide them to specific cell types, helping ensure that the package is not just delivered to the right neighborhood but also arrives at the correct house—and, crucially, gains entry inside, where the therapeutic payload can actually be used.
These vesicles are not random messengers. Instead, they carry built-in targeting signals that direct them to specific cell types. This raises a powerful possibility: rather than engineering synthetic delivery systems, it may be possible to harness naturally occurring vesicles that already “know” where to go.
This idea was tested by collecting vesicles from different cell types, tracking their movement through the body and assessing whether they successfully delivered their cargo to target cells. This last point is critical. Many delivery systems can reach an organ, but far fewer enter the right cells and release their payload.
Brain delivery is assessed by injecting vesicles into the cerebrospinal fluid surrounding the brain and spinal cord in mice carrying a gene linked to dementia. The vesicles from specific brain-related cell types reduced expression of the target gene by roughly 50% to 80% across multiple brain regions, including areas typically difficult to access. Vesicles from other sources, including commonly used lab cells, show little to no detectable effect. In monkeys, the same approach achieves up to 80% gene silencing in outer brain regions and 60% in deeper memory-related structures. The treatment spreads well beyond the injection site, and no detectable inflammation or behavioral changes were reported.
For kidney targeting, vesicles from young skin cells proved especially effective. These vesicles traveled through the bloodstream and localized in the kidney’s filtering units, the precise location where certain disease-causing genes are active. In a mouse model of kidney disease, the treatment reduced target gene activity by up to 90% and decreased protein leakage into urine by more than 85%. The kidney’s structural damage improved significantly. In a second model, gene silencing reversed scarring to near-normal levels. In rabbits, the same strategy achieved more than 70% gene silencing in the kidney, suggesting this approach can scale effectively.
These vesicles naturally target specific cells and efficiently deliver their contents, thereby requiring much less drug. Conventional approaches to kidney delivery can require doses up to 50 times those used for liver-targeted therapies. The vesicle-based system achieved results equal to or better than those with roughly one-fiftieth the amount. At these lower doses, no significant toxicity, immune reactions, or organ damage was observed in the models.
The results remain preclinical, demonstrated in mice, rabbits and a limited number of monkeys. Further work is needed to scale production, confirm durability and establish safety in larger studies before human trials can begin. Even so, the implications are significant.
If naturally derived vesicles can reliably deliver gene therapies to specific cell types, they could mark the beginning of a new era in medicine—one defined by precise biological targeting.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。